[The treatment of deep venous thrombosis using low-molecular heparin. Swiss Consensus Conference for the Application of Low-molecular Heparin].
Bachmann
F
F
Département de médecine interne, CHUV, Hôpital Nestlé, Lausanne.
D000818:Animals; D001682:Biological Availability; D017985:Dalteparin / Q000627:therapeutic use; D017984:Enoxaparin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D017762:Nadroparin / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000517:prevention & control; D013927:Thrombosis / Q000188:drug therapy*
D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; C079002:Logiparin; D017762:Nadroparin; C089749:Sandoparin; D006493:Heparin; D017985:Dalteparin
Die Behandlung der tiefen Venenthrombose mit niedermolekularem Heparin.